Covered recipient · General Payments record
YUAN YUAN
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$196,385.09
125 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $134,615.00 | 38 |
| Consulting Fee | $35,414.25 | 17 |
| Travel and Lodging | $21,152.16 | 30 |
| Food and Beverage | $3,703.68 | 39 |
| Honoraria | $1,500.00 | 1 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $79,497.25 | 49 |
| Gilead Sciences, Inc. | $74,819.20 | 44 |
| Merck Sharp & Dohme LLC | $15,033.62 | 13 |
| Daiichi Sankyo Inc. | $9,238.52 | 8 |
| Novartis Pharmaceuticals Corporation | $8,679.74 | 4 |
| PFIZER INC. | $3,618.76 | 2 |
| Genentech USA, Inc. | $1,650.00 | 1 |
| MACROGENICS, INC. | $1,500.00 | 1 |
| TerSera Therapeutics LLC | $1,078.00 | 1 |
| EISAI INC. | $760.00 | 1 |
| Stemline Therapeutics Inc. | $510.00 | 1 |
Page 2 of 3; records 51–100 of 125 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
YUAN YUAN
NPI 1073664660 · CMS profile ID 963347
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
PASADENA, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 125 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1073664660?year=2022&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- YUAN YUAN, NPI 1073664660, CMS profile ID 963347. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 125 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073664660?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). YUAN YUAN, NPI 1073664660, CMS profile ID 963347. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 125 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073664660?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- YUAN YUAN, NPI 1073664660, CMS profile ID 963347, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 125 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1073664660?year=2022&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
125 matching records · $196,385.09 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 125.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | $5,140.00 | 07/07/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929442681 | CMS |
| Gilead Sciences, Inc. | $6,610.00 | 06/30/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929448859 | CMS |
| AstraZeneca Pharmaceuticals LP | $5,500.00 | 06/29/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915465313 | CMS |
| Gilead Sciences, Inc. | $1,265.00 | 06/29/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929471669 | CMS |
| Gilead Sciences, Inc. | $125.00 | 06/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929586695 | CMS |
| AstraZeneca Pharmaceuticals LP | $94.63 | 06/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915041163 | CMS |
| AstraZeneca Pharmaceuticals LP | $781.13 | 06/28/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915134069 | CMS |
| Merck Sharp & Dohme LLC | $4,270.00 | 06/24/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944038807 | CMS |
| Merck Sharp & Dohme LLC | $75.00 | 06/23/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944038797 | CMS |
| AstraZeneca Pharmaceuticals LP | $123.68 | 06/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914762027 | CMS |
| AstraZeneca Pharmaceuticals LP | $164.36 | 06/22/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915250425 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,629.37 | 06/22/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915883923 | CMS |
| Gilead Sciences, Inc. | $3,170.00 | 06/22/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929448851 | CMS |
| AstraZeneca Pharmaceuticals LP | $5,500.00 | 06/20/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915332319 | CMS |
| Daiichi Sankyo Inc. | $4,100.00 | 06/20/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930840447 | CMS |
| Gilead Sciences, Inc. | $3,950.00 | 06/20/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929442665 | CMS |
| Gilead Sciences, Inc. | $9.21 | 06/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929586669 | CMS |
| Gilead Sciences, Inc. | $24.99 | 06/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929586671 | CMS |
| Gilead Sciences, Inc. | $49.99 | 06/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929586679 | CMS |
| Gilead Sciences, Inc. | $49.99 | 06/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929586681 | CMS |
| Gilead Sciences, Inc. | $181.56 | 06/17/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929471623 | CMS |
| Gilead Sciences, Inc. | $1,027.20 | 06/17/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929471663 | CMS |
| Daiichi Sankyo Inc. | $541.21 | 06/15/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930838069 | CMS |
| Daiichi Sankyo Inc. | $159.74 | 06/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930840561 | CMS |
| Gilead Sciences, Inc. | $764.00 | 06/14/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929471657 | CMS |
| Gilead Sciences, Inc. | $124.83 | 06/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929586693 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,133.02 | 06/09/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914749173 | CMS |
| AstraZeneca Pharmaceuticals LP | $287.83 | 06/09/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915058711 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.00 | 06/09/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915084887 | CMS |
| AstraZeneca Pharmaceuticals LP | $100.00 | 06/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915252997 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,750.00 | 06/09/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915271485 | CMS |
| AstraZeneca Pharmaceuticals LP | $123.69 | 06/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915846437 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,350.00 | 06/07/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914695031 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,350.00 | 06/06/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914698801 | CMS |
| Novartis Pharmaceuticals Corporation | $73.49 | 06/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894464405 | CMS |
| AstraZeneca Pharmaceuticals LP | $108.11 | 05/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914659963 | CMS |
| AstraZeneca Pharmaceuticals LP | $735.09 | 05/31/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915295941 | CMS |
| AstraZeneca Pharmaceuticals LP | $5,500.00 | 05/26/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915614881 | CMS |
| AstraZeneca Pharmaceuticals LP | $5,500.00 | 05/26/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915633603 | CMS |
| Merck Sharp & Dohme LLC | $582.40 | 05/19/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944038803 | CMS |
| Merck Sharp & Dohme LLC | $124.99 | 05/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944296598 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,828.20 | 05/18/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914801121 | CMS |
| AstraZeneca Pharmaceuticals LP | $124.99 | 05/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914972261 | CMS |
| Gilead Sciences, Inc. | $3,950.00 | 05/18/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929442661 | CMS |
| Gilead Sciences, Inc. | $7,190.00 | 05/18/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929442693 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,750.00 | 05/17/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914896309 | CMS |
| Gilead Sciences, Inc. | $655.08 | 05/16/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929471651 | CMS |
| Gilead Sciences, Inc. | $110.36 | 05/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929586689 | CMS |
| AstraZeneca Pharmaceuticals LP | $125.00 | 05/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915162175 | CMS |
| AstraZeneca Pharmaceuticals LP | $113.63 | 05/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915076929 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $381,262.05 | 17 |
| PY2024 | Principal investigator | $594,137.78 | 26 |
| PY2023 | Recipient | $1,400.00 | 1 |
| PY2023 | Principal investigator | $432,122.35 | 25 |
| PY2022 | Recipient | $9,080.00 | 4 |
| PY2022 | Principal investigator | $1,073,794.38 | 21 |
| PY2021 | Recipient | $2,220.00 | 4 |
| PY2021 | Principal investigator | $1,831,076.90 | 22 |
| PY2020 | Recipient | $729.20 | 1 |
| PY2020 | Principal investigator | $1,814,767.93 | 49 |
| PY2019 | Principal investigator | $2,877,864.74 | 80 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
17 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $2,529.76 | 12/31/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer TNBC | No dispute reported | 06/30/2026 | 1232925821 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $4,253.54 | 12/31/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Re | No dispute reported | 06/30/2026 | 1232926941 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $153,363.92 | 12/31/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | Open Label, Phase II Pilot Study of Immune Checkpoint Inhibition with Pembrolizumab in Combination with PARP Inhibition with Olaparib in Advanced BRCA-mutated Breast Cancers | No dispute reported | 06/30/2026 | 1232932547 |
| Principal investigator 1 | PFIZER INC. | $10,000.00 | 10/31/2025 | Covered Recipient Teaching Hospital HUNTINGTON HOSPITAL | THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CANCER COMPASSHER2 RESIDUAL DISEASE RD A DOUBLEBLINDED PHASE III RANDOMIZED TRIAL OF TDM1 COMPARED WITH TDM1 AND TUCATINIB | No dispute reported | 06/30/2026 | 1228720959 |
| Principal investigator 1 | PFIZER INC. | $10,000.00 | 10/31/2025 | Non-covered Recipient Entity NRG Oncology Foundation | THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CANCER COMPASSHER2 RESIDUAL DISEASE RD A DOUBLEBLINDED PHASE III RANDOMIZED TRIAL OF TDM1 COMPARED WITH TDM1 AND TUCATINIB | No dispute reported | 06/30/2026 | 1228721101 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $11,885.23 | 06/18/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | U31402-308 | No dispute reported | 06/30/2026 | 1223345254 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $10,972.93 | 06/18/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | U31402-308 | No dispute reported | 06/30/2026 | 1223345256 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15,905.19 | 06/18/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | U31402-308 | No dispute reported | 06/30/2026 | 1223345258 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $3,377.38 | 06/16/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Re | No dispute reported | 06/30/2026 | 1232926939 |
| Principal investigator 1 | Genentech, Inc. | $2,600.00 | 06/10/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC | No dispute reported | 06/30/2026 | 1211542218 |
| Principal investigator 1 | Genentech, Inc. | $2,600.00 | 06/03/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC | No dispute reported | 06/30/2026 | 1211542211 |
| Principal investigator 1 | Eli Lilly and Company | $21.90 | 05/27/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF NEUROLOGY LP | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 1187882940 |
| Principal investigator 1 | Eli Lilly and Company | $4,135.00 | 04/01/2025 | Covered Recipient Teaching Hospital CEDARS-SINAI MEDICAL CENTER | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 1187872567 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $15,461.39 | 02/28/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF DATO-DXD VERSUS INVESTIGATORS CHOICE OF CHEMOTHERAPY IN PARTICIPANTS WITH INOPERABLE OR METASTATIC HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER WHO HAVE BEEN TREATED WITH ONE OR TWO PRIOR LINES OF SYSTEMIC CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1185540703 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $98,844.56 | 02/10/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | U31402-308 | No dispute reported | 06/30/2026 | 1223345260 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $35,300.30 | 01/30/2025 | Covered Recipient Teaching Hospital Cedars-Sinai Medical Center | Open Label, Phase II Pilot Study of Immune Checkpoint Inhibition with Pembrolizumab in Combination with PARP Inhibition with Olaparib in Advanced BRCA-mutated Breast Cancers | No dispute reported | 06/30/2026 | 1232932315 |
| Principal investigator 1 | Eli Lilly and Company | $10.95 | 01/27/2025 | Non-covered Recipient Entity TORRANCE MEMORIAL MEDICAL CENTER | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | No dispute reported | 06/30/2026 | 1187892856 |